ProfileGDS5678 / 1435419_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 19% 19% 19% 19% 18% 19% 19% 19% 19% 19% 19% 19% 19% 19% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4909519
GSM967853U87-EV human glioblastoma xenograft - Control 22.4593419
GSM967854U87-EV human glioblastoma xenograft - Control 32.4626119
GSM967855U87-EV human glioblastoma xenograft - Control 42.403719
GSM967856U87-EV human glioblastoma xenograft - Control 52.3931918
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5218919
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4962619
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4306619
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4262419
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4463919
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4410319
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.42319
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.447819
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4440119